Cargando…
Management of hepatitis C genotype 4 in the directly acting antivirals era
Genotype 4 chronic hepatitis C (G4 HCV) accounts for 13% of worldwide HCV infections; with 10 million people infected with the virus across the world. Up to the end of 2013, the only treatment option for G4 HCV was treatment with pegylated interferon and ribavirin for 24–48 weeks. Since late 2013, t...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051320/ https://www.ncbi.nlm.nih.gov/pubmed/27752338 http://dx.doi.org/10.1136/bmjgast-2016-000112 |